Pharmaceuticals Why Biopharmaceutical CEOs Can’t Delegate Responsible AI to Their Chief Legal Officers Last updated: August 22, 2024 1:05 pm By bexib 0 Min Read Share SHARE The Harvard Business School Healthcare Alumni Association will host a Q&A with Kevin Werbach, professor of law and business ethics at the Wharton School. You Might Also Like APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins New ways to determine drug value with health equity in mind Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer Share This Article Facebook Twitter Email Print Previous Article SJ’s Declassified Metal Printing Starter Guide Next Article Death of the engineer CEO: Evidence of the ascendancy of short-termism and financialization Leave a comment Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Stay ConnectedFacebookLikeTwitterFollowYoutubeSubscribeTelegramFollowLatest News How to reduce shipping costs for small businesses International Shipping Demand for self-service banking grows – Bank Automation News Banking Building India’s Future : A Deep Dive with Mr Dimitrov Krishnan, MD Volvo Construction Equipment Manufacturing 5th Samurai Awards & Conference 2024: Celebrating Manufacturing and Supply Chain Excellence Manufacturing